Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 5/20 | 0.64 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | POLB | P06746 | 6/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.50 |
| ▸ | CTDSP1 | Q9GZU7 | 5/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | MMP1 | P03956 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | MMP9 | P14780 | 1/20 | 0.47 |
| ▸ | MMP8 | P22894 | 1/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
| ▸ | LOX | P28300 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.45 |
| ▸ | GRK2 | P25098 | 2/20 | 0.45 |
| ▸ | RECQL | P46063 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | APEX1 | P27695 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9325260 | 0.89 | CA2 (0.78) | CA2PLCG1KMT2APOLBLOX | |
| SCHEMBL1941210 | 0.88 | CA2 (0.67) | CA2PLCG1KMT2APOLBHSD11B1 | |
| SCHEMBL10792219 | 0.82 | CA2 (0.69) | CA2POLBMMP1MMP2MMP9 | |
| SCHEMBL17118225 | 0.82 | PLCG1 (0.67) | CA2PLCG1KMT2APOLBHSD11B1 | |
| SCHEMBL19127744 | 0.80 | PLCG1 (0.64) | CA2PLCG1KMT2APOLBHSD11B1 | |
| SCHEMBL9473149 | 0.80 | CA2 (0.67) | CA2KMT2APOLBLOXMEN1 | |
| SCHEMBL2593583 | 0.80 | CA2 (0.67) | CA2KMT2APOLBCA1MMP2 | |
| SCHEMBL12336517 | 0.80 | CA2 (0.67) | CA2KMT2APOLBLOXTDP1 | |
| SCHEMBL17674086 | 0.79 | PLCG1 (0.47) | CA2PLCG1KMT2APOLBHSD11B1 | |
| SCHEMBL5664200 | 0.78 | CA2 (0.64) | CA2KMT2APOLBHSD11B1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240140933-A1 | OXOINDOLINE COMPOUND FOR THE TREATMENT OF INFLAMMATORY DISEASES OR CANCER | HOFFMANN-LA ROCHE INC. (US) | 2024-05-02 | — | — | US | disclosed |
| EP-4341252-A1 | OXOINDOLINE COMPOUND FOR THE TREATMENT OF INFLAMMATORY DISEASES OR CANCER | F. Hoffmann-La Roche AG (CH) | 2024-03-27 | — | — | EP | disclosed |
| EP-3681883-B1 | DIPHENYL DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2024-02-21 | — | — | EP | disclosed |
| US-11787781-B2 | Inhibiting ataxia telangiectasia and RAD3-related protein (ATR) | CELATOR PHARMACEUTICALS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787781-B2 | Inhibiting ataxia telangiectasia and RAD3-related protein (ATR) | CELATOR PHARMACEUTICALS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| CN-110997654-B | Indole derivatives and uses thereof | 诺华股份有限公司 | 2023-08-15 | — | — | CN | disclosed |
| CN-111094278-B | Diphenyl derivative and use thereof | 诺华股份有限公司 | 2023-07-14 | — | — | CN | disclosed |
| WO-2022243346-A1 | OXOINDOLINE COMPOUND FOR THE TREATMENT OF INFLAMMATORY DISEASES OR CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2022-11-24 | — | — | WO | disclosed |
| EP-3658546-B1 | INDOLE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2022-10-26 | — | — | EP | disclosed |
| EP-3936153-A1 | INHIBITING ATAXIA TELANGIECTASIA AND RAD3-RELATED PROTEIN (ATR) | Celator Pharmaceuticals, Inc. (US) | 2022-01-12 | — | — | EP | disclosed |
| US-20080103141-A1 | New compounds | BIOVITRUM (SE) | 2008-05-01 | — | — | US | disclosed |
| US-20080103123-A1 | New compounds | BIOVITRUM (SE) | 2008-05-01 | — | — | US | disclosed |
| WO-2008048609-A1 | BIPHENYL SULFONYL AND PHENYL-HETEROARYL SULFONYL MODULATORS OF THE HISTAMINE H3-RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2008-04-24 | — | — | WO | disclosed |
| WO-2008025800-A1 | PYRIMIDINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS | BIOVITRUM AB (PUBL) (SE) | 2008-03-06 | — | — | WO | disclosed |
| WO-2008025798-A1 | PYRIDINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS | BIOVITRUM AB (PUBL) (SE) | 2008-03-06 | — | — | WO | disclosed |
| WO-2007093772-A1 | PROCESS FOR THE PREPARATION OF 2- [VINYL (HETERO) ARYL SULPHONYL] ETHANOL DERIVATIVES | UNIVERSITY OF DURHAM (GB) | 2007-08-23 | — | — | WO | disclosed |
| WO-2007040440-A1 | NEW PYRIMIDINE DERIVATIVES AND THEIR USE IN THERAPY AS WELL AS THE USE OF PYRIMIDINE DERIVATIVES IN THE MANUFACTURE OF A MEDICAMENT FOR PREVENTION AND/OR TREATMENT OF ALZHEIMER’S DISEASE | ASTRAZENECA AB (SE) | 2007-04-12 | — | — | WO | disclosed |
| EP-0841323-B1 | Method for producing arylvinylsulfone | SUMITOMO CHEMICAL CO (JP) | 2003-03-05 | — | — | EP | disclosed |
| US-5902905-A | Method for producing arylvinylsulfone | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1999-05-11 | — | — | US | disclosed |
| EP-0841323-A2 | Method for producing arylvinylsulfone | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 1998-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240140933-A1 | OXOINDOLINE COMPOUND FOR THE TREATMENT OF INFLAMMATORY DISEASES OR CANCER | IL1B, IL1A, IL1R1 | CA2 2708/4885PLCG1 4752/4885KMT2A 2242/4885 |
| US-20080103141-A1 | New compounds | GPR119, GPR3, GPR4 | CA2 1140/4885PLCG1 3526/4885KMT2A 4781/4885 |
| US-20080103123-A1 | New compounds | GPR119, GPR139, GPR180 | CA2 1045/4885PLCG1 3419/4885KMT2A 4721/4885 |
| US-11787781-B2 | Inhibiting ataxia telangiectasia and RAD3-related protein (ATR) | ATR, CHEK2, CHEK1 | CA2 4737/4885PLCG1 1342/4885KMT2A 2692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.